Corbus Pharmaceuticals (CRBP) Financials

Corbus Pharmaceuticals logo
$3.38 -0.01 (-0.29%)
Closing price 04:00 PM Eastern
Extended Trading
$3.47 +0.09 (+2.66%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Corbus Pharmaceuticals

Annual Income Statements for Corbus Pharmaceuticals

This table shows Corbus Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-8.85 -20 -32 -56 -71 -100 -46 -42 -44 -40 -79
Consolidated Net Income / (Loss)
-8.85 -20 -32 -56 -71 -223 -91 -85 -89 -80 -157
Net Income / (Loss) Continuing Operations
-8.85 -20 -32 -56 -71 -100 -46 -85 -89 -80 -157
Total Pre-Tax Income
-8.85 -20 -32 -56 -71 -111 -46 -85 -89 -80 -157
Total Operating Income
-8.85 -20 -33 -57 -77 -123 -56 -40 -45 -49 -85
Total Gross Profit
0.65 1.91 2.44 4.82 36 3.94 0.88 0.00 1.64 6.31 5.53
Total Revenue
0.65 1.91 2.44 4.82 36 3.94 0.88 0.00 1.64 6.31 5.53
Operating Revenue
0.65 1.91 2.44 4.82 36 3.94 0.88 0.00 1.64 6.31 5.53
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
9.50 22 35 62 113 127 57 80 90 97 171
Selling, General & Admin Expense
3.61 6.46 8.96 13 24 28 20 19 14 16 15
Research & Development Expense
5.89 15 26 49 90 98 36 16 31 32 70
Other Operating Expenses / (Income)
- - - - - - - 40 45 49 85
Other Special Charges / (Income)
- - - - - - 0.00 5.00 0.00 0.00 0.00
Total Other Income / (Expense), net
0.00 -0.01 0.14 1.08 5.65 12 10 -5.09 -0.56 11 7.93
Interest Expense
- - - - -1.23 1.03 1.83 2.13 3.86 1.87 0.00
Other Income / (Expense), net
0.00 -0.01 -0.04 0.09 4.42 13 12 -2.95 3.30 13 7.93
Basic Earnings per Share
($0.28) ($0.49) ($0.65) ($0.98) ($1.12) ($1.42) ($11.15) ($10.15) ($10.31) ($3.68) ($5.90)
Weighted Average Basic Shares Outstanding
31.35M 41.14M 50.18M 57.00M 63.90M 78.13M 4.09M 4.17M 4.33M 10.92M 13.32M
Diluted Earnings per Share
($0.28) ($0.49) ($0.65) ($0.98) ($1.12) ($1.42) ($11.15) ($10.15) ($10.31) ($3.68) ($5.90)
Weighted Average Diluted Shares Outstanding
31.35M 41.14M 50.18M 57.00M 63.90M 78.13M 4.09M 4.17M 4.33M 10.92M 13.32M
Weighted Average Basic & Diluted Shares Outstanding
31.35M 41.14M 50.18M 57.00M 63.90M 78.13M 122.99M 4.17M 10.49M 12.23M 17.74M

Quarterly Income Statements for Corbus Pharmaceuticals

This table shows Corbus Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-7.93 -10 -16 -6.41 -17 -18 -23 -21 -23 -35 -38
Consolidated Net Income / (Loss)
-14 -20 -28 -19 -34 -18 -23 -41 -46 -35 -38
Net Income / (Loss) Continuing Operations
-7.93 -20 -16 -37 -34 -18 -23 -41 -46 -35 -38
Total Pre-Tax Income
-7.93 -20 -16 -37 -34 -18 -23 -41 -46 -35 -38
Total Operating Income
-9.62 -11 -16 -13 -20 -19 -24 -22 -24 -36 -39
Total Gross Profit
0.00 1.60 0.00 4.71 1.68 1.31 1.13 1.41 1.40 1.16 1.08
Total Revenue
0.00 1.60 0.00 4.71 1.68 1.31 1.13 1.41 1.40 1.16 1.08
Operating Revenue
- 1.60 - - 1.68 1.31 1.13 1.41 1.40 1.16 1.08
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
9.62 22 16 50 40 19 24 44 49 36 39
Selling, General & Admin Expense
3.86 4.12 4.70 3.82 4.13 3.97 3.56 3.56 4.49 5.02 4.58
Research & Development Expense
5.76 6.87 11 8.79 16 15 21 18 20 31 34
Total Other Income / (Expense), net
1.70 0.32 -0.18 8.91 3.86 0.18 -0.05 1.36 1.16 -0.01 -0.01
Interest Expense
0.84 0.65 0.38 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Other Income / (Expense), net
2.54 0.98 0.20 8.91 3.86 0.18 -0.05 1.36 1.16 -0.01 -0.01
Basic Earnings per Share
($0.83) ($0.90) ($1.15) ($0.59) ($1.39) ($1.44) ($1.90) ($1.17) ($1.23) ($1.81) ($1.81)
Weighted Average Basic Shares Outstanding
8.31M 11.05M 12.01M 10.92M 12.20M 12.24M 12.31M 13.32M 18.71M 19.41M 20.84M
Diluted Earnings per Share
($0.83) ($0.90) ($1.15) ($0.59) ($1.39) ($1.44) ($1.90) ($1.17) ($1.23) ($1.81) ($1.81)
Weighted Average Diluted Shares Outstanding
8.31M 11.05M 12.01M 10.92M 12.20M 12.24M 12.31M 13.32M 18.71M 19.41M 20.84M
Weighted Average Basic & Diluted Shares Outstanding
10.69M 12.04M 12.18M 12.23M 12.24M 12.26M 17.55M 17.74M 18.53M 19.34M 20.61M

Annual Cash Flow Statements for Corbus Pharmaceuticals

This table details how cash moves in and out of Corbus Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
6.10 2.82 48 -21 -10.00 55 -61 -8.00 -3.28 3.47 11
Net Cash From Operating Activities
-4.62 -14 -28 -30 -46 -100 -48 -38 -36 -42 -64
Net Cash From Continuing Operating Activities
-4.62 -14 -28 -30 -46 -100 -48 -38 -36 -42 -64
Net Income / (Loss) Continuing Operations
-8.85 -20 -32 -56 -71 -111 -46 -42 -45 -40 -79
Consolidated Net Income / (Loss)
-8.85 -20 -32 -56 -71 -111 -46 -42 -45 -40 -79
Depreciation Expense
0.04 0.09 0.26 0.49 0.74 1.12 1.00 0.76 0.64 0.59 0.23
Amortization Expense
- - - - 0.49 0.86 2.04 0.87 0.32 -2.93 -1.37
Non-Cash Adjustments To Reconcile Net Income
1.15 3.18 5.69 8.10 9.35 14 12 7.20 4.27 7.26 7.11
Changes in Operating Assets and Liabilities, net
3.03 3.16 -1.32 17 15 -4.27 -17 -4.02 3.27 -6.46 8.07
Net Cash From Investing Activities
-0.11 -0.35 -0.71 -2.30 -2.74 -0.48 -73 30 36 -121 -1.64
Net Cash From Continuing Investing Activities
-0.11 -0.35 -0.71 -2.30 -2.74 -0.48 -73 30 36 -121 -1.64
Purchase of Property, Plant & Equipment
-0.11 -0.35 -0.71 -2.30 -2.74 -0.48 -0.05 -0.01 0.00 0.00 -0.01
Purchase of Investments
- - - - - 0.00 -87 -86 -34 -181 -163
Sale and/or Maturity of Investments
- - - - - 0.00 14 116 70 59 161
Net Cash From Financing Activities
11 17 76 11 38 155 61 -0.53 -2.82 167 77
Net Cash From Continuing Financing Activities
11 17 76 11 38 155 61 -0.53 -2.82 167 77
Repayment of Debt
-0.19 -0.24 -0.36 -0.43 -0.61 -0.95 -0.93 -2.37 -3.25 -15 0.00
Issuance of Common Equity
11 17 79 12 41 142 63 0.00 0.05 182 77
Cash Interest Paid
0.00 0.01 0.01 0.01 0.03 0.63 1.74 1.97 2.61 2.82 0.00

Quarterly Cash Flow Statements for Corbus Pharmaceuticals

This table details how cash moves in and out of Corbus Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
0.38 9.58 -4.26 -2.23 1.70 1.14 6.94 1.51 -3.12 -2.29 6.88
Net Cash From Operating Activities
-7.97 -8.94 -14 -11 -16 -17 -16 -16 -26 -30 -21
Net Cash From Continuing Operating Activities
-7.92 -8.99 -14 -11 -16 -17 -16 -16 -26 -30 -21
Net Income / (Loss) Continuing Operations
-6.90 -10.00 -14 -9.53 -17 -18 -23 -21 -23 -35 -38
Consolidated Net Income / (Loss)
-6.90 -10.00 -14 -9.53 -17 -18 -23 -21 -23 -35 -38
Depreciation Expense
0.15 0.15 0.15 0.13 0.08 0.05 0.05 0.05 0.05 0.05 0.05
Amortization Expense
-0.72 -0.83 -0.56 -0.83 -0.20 -0.62 -0.05 -0.69 -0.35 -0.23 -0.19
Non-Cash Adjustments To Reconcile Net Income
1.21 1.47 2.51 2.08 1.68 1.78 1.90 1.72 2.00 1.82 1.81
Changes in Operating Assets and Liabilities, net
-1.66 0.22 -2.26 -2.75 -1.00 -0.14 5.90 3.56 -4.31 3.77 15
Net Cash From Investing Activities
-98 -16 -15 8.73 18 18 20 -57 22 18 9.56
Net Cash From Continuing Investing Activities
-98 -16 -15 8.73 18 18 20 -57 22 18 9.56
Purchase of Property, Plant & Equipment
- - - - 0.00 - - - -0.01 -0.01 -0.02
Purchase of Investments
-106 -25 -39 -11 -38 -18 -18 -90 -11 -8.70 -44
Sale and/or Maturity of Investments
7.66 8.39 23 20 56 35 37 33 33 27 53
Net Cash From Financing Activities
107 35 25 -0.01 0.00 - 2.85 75 0.00 9.08 19
Net Cash From Continuing Financing Activities
107 35 25 -0.01 0.00 - 2.85 75 0.00 9.08 19
Issuance of Common Equity
109 37 36 -0.01 0.00 - 2.85 75 0.00 9.08 19

Annual Balance Sheets for Corbus Pharmaceuticals

This table presents Corbus Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
13 18 67 47 49 102 108 66 28 156 168
Total Current Assets
13 17 66 44 38 92 100 60 24 153 167
Cash & Equivalents
12 15 63 42 32 85 25 17 14 17 28
Restricted Cash
0.00 0.15 0.16 - 0.00 0.35 0.19 0.19 0.19 0.29 0.67
Short-Term Investments
- - - - - - 73 42 7.18 132 135
Prepaid Expenses
0.38 0.93 2.81 2.49 3.72 3.71 2.37 0.79 2.45 3.63 3.02
Plant, Property, & Equipment, net
0.12 0.44 1.43 2.71 5.08 4.07 2.39 1.61 0.97 0.39 0.16
Total Noncurrent Assets
0.04 0.05 0.04 0.04 5.90 6.15 5.13 4.52 3.75 2.52 1.08
Other Noncurrent Operating Assets
- 0.00 0.04 0.04 5.90 6.15 5.13 4.52 3.75 2.52 1.08
Total Liabilities & Shareholders' Equity
13 18 67 47 49 102 108 66 28 156 168
Total Liabilities
3.89 8.97 9.19 19 43 57 39 33 35 13 21
Total Current Liabilities
3.63 8.90 8.20 18 35 32 17 13 32 12 21
Accounts Payable
1.31 3.42 3.13 6.35 11 7.38 1.78 2.17 3.18 4.79 2.22
Accrued Expenses
0.56 3.26 4.74 9.85 22 22 10 6.00 11 5.43 17
Other Current Liabilities
- - - 0.00 0.60 1.80 1.27 1.32 17 1.61 1.63
Total Noncurrent Liabilities
0.26 0.07 0.99 1.38 8.10 25 22 21 3.28 1.63 0.00
Capital Lease Obligations
- - - - - - - 4.68 3.24 - 0.00
Total Equity & Noncontrolling Interests
8.99 8.92 58 28 6.16 45 69 33 -6.91 142 148
Total Preferred & Common Equity
8.99 8.92 58 28 6.16 45 69 33 -6.91 142 148
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
8.99 8.92 58 28 6.16 45 69 33 -6.91 142 148
Common Stock
22 42 123 149 199 349 419 425 430 619 703
Retained Earnings
-13 -33 -66 -121 -193 -304 -350 -392 -437 -477 -555
Accumulated Other Comprehensive Income / (Loss)
- - - - - 0.00 -0.06 -0.13 -0.00 0.04 -0.05

Quarterly Balance Sheets for Corbus Pharmaceuticals

This table presents Corbus Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
36 126 152 164 140 125 110 144 127 123
Total Current Assets
31 122 148 161 137 123 108 144 123 119
Cash & Equivalents
11 14 24 19 19 20 27 26 23 30
Restricted Cash
0.19 0.28 0.29 0.29 0.29 0.29 0.29 0.39 0.00 0.00
Short-Term Investments
17 106 123 140 114 97 77 113 95 85
Prepaid Expenses
2.28 1.31 1.00 1.24 4.29 5.95 3.30 4.96 4.81 3.61
Plant, Property, & Equipment, net
1.12 0.82 0.67 0.52 0.30 0.25 0.20 0.12 0.07 0.04
Total Noncurrent Assets
3.96 3.23 3.00 2.76 2.27 2.01 1.74 0.80 4.16 3.92
Other Noncurrent Operating Assets
3.96 3.23 3.00 2.76 2.27 2.01 1.74 0.80 4.16 3.92
Total Liabilities & Shareholders' Equity
36 126 152 164 140 125 110 144 127 123
Total Liabilities
36 29 26 14 13 14 17 18 25 38
Total Current Liabilities
32 26 24 12 12 13 17 18 21 35
Accounts Payable
4.71 2.08 1.15 2.89 4.07 3.99 2.74 0.44 5.25 4.07
Accrued Expenses
7.55 9.40 10 7.18 5.90 7.65 13 16 15 30
Other Current Liabilities
1.43 1.49 12 1.56 1.65 1.70 1.74 1.21 1.00 0.73
Total Noncurrent Liabilities
4.43 2.86 2.46 2.05 1.21 0.76 0.31 0.00 3.27 3.18
Capital Lease Obligations
3.61 2.86 2.46 2.05 1.21 0.76 0.31 0.00 - 3.18
Total Equity & Noncontrolling Interests
0.31 97 126 150 127 111 92 126 102 85
Total Preferred & Common Equity
0.31 97 126 150 127 111 92 126 102 85
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
0.31 97 126 150 127 111 92 126 102 85
Common Stock
429 541 580 618 621 623 627 705 716 736
Retained Earnings
-429 -444 -454 -467 -494 -512 -535 -578 -613 -651
Accumulated Other Comprehensive Income / (Loss)
-0.01 -0.33 -0.39 0.21 -0.02 -0.04 -0.00 -0.16 -0.11 -0.20

Annual Metrics And Ratios for Corbus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Corbus Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
37,605,134.00 44,437,673.00 54,873,010.00 57,237,496.00 64,672,893.00 84,037,239.00 125,230,881.00 125,280,881.00 4,423,683.00 12,179,482.00 17,553,037.00
DEI Adjusted Shares Outstanding
1,253,504.00 1,481,256.00 1,829,100.00 1,907,917.00 2,155,763.00 2,801,241.00 4,174,363.00 4,176,029.00 4,423,683.00 12,179,482.00 17,553,037.00
DEI Earnings Per Adjusted Shares Outstanding
-7.06 -13.50 -17.73 -29.18 -33.15 -35.60 -10.93 -10.17 -10.03 -3.30 -4.48
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 194.80% 27.66% 97.62% 649.51% -89.11% -77.61% -100.00% 0.00% 285.76% -12.38%
EBITDA Growth
-234.62% -126.07% -62.46% -73.61% -27.23% -51.51% 62.34% -0.95% 0.82% 5.83% -104.24%
EBIT Growth
-234.96% -125.94% -63.03% -73.76% -28.29% -51.68% 60.26% 2.33% 2.35% 13.60% -114.35%
NOPAT Growth
-234.46% -125.73% -62.94% -74.27% -35.87% -59.28% 54.41% 28.85% -13.16% -8.08% -75.10%
Net Income Growth
-248.39% -125.95% -62.12% -71.71% -28.35% -211.44% 58.98% 7.22% -5.33% 9.85% -95.32%
EPS Growth
-115.38% -75.00% -32.65% -50.77% -14.29% -26.79% 58.98% 7.22% -1.58% 64.31% -60.33%
Operating Cash Flow Growth
-95.86% -193.44% -104.82% -8.17% -52.06% -118.03% 51.66% 22.08% 3.85% -15.77% -54.31%
Free Cash Flow Firm Growth
-75.43% -246.27% -115.90% -25.84% -40.99% -107.23% 41.90% 33.25% 71.96% -433.43% 2.80%
Invested Capital Growth
-1,099.63% -85.93% 23.68% -201.96% -79.60% 12.36% 57.58% 71.94% -844.26% 71.72% -137.55%
Revenue Q/Q Growth
128.23% 0.60% -13.34% 66.57% 1.82% -32.73% -42.74% 0.00% 0.00% 95.02% -37.38%
EBITDA Q/Q Growth
-16.18% -34.06% -11.06% -13.39% -6.66% 12.10% -2.87% -9.68% 13.59% 3.23% -27.35%
EBIT Q/Q Growth
-16.27% -33.97% -11.10% -13.47% -7.50% 11.77% -4.65% -6.20% 13.35% 5.83% -27.96%
NOPAT Q/Q Growth
-16.31% -34.01% -11.24% -13.45% -14.22% 4.94% 16.19% -2.05% 1.51% -5.41% -12.33%
Net Income Q/Q Growth
-16.27% -33.98% -10.66% -13.48% -14.92% -35.58% 40.56% -17.01% 17.53% -3.90% -16.33%
EPS Q/Q Growth
0.00% -32.43% -3.17% -11.36% -9.80% 10.69% 40.56% -17.01% 3.73% -6.05% -12.60%
Operating Cash Flow Q/Q Growth
8.69% -51.23% -15.05% -19.71% -22.83% 4.17% 15.03% 5.65% 3.85% -13.39% -8.37%
Free Cash Flow Firm Q/Q Growth
0.00% -68.14% -12.86% -12.69% -23.34% -10.60% 27.17% 9.14% 61.40% -59.37% -3.61%
Invested Capital Q/Q Growth
-60.35% -3.80% 4.92% -8.14% 1.47% 38.05% 15.10% -1,202.85% -241.93% 2.56% -39.13%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin
-1,358.42% -1,041.71% -1,325.68% -1,164.62% -197.69% -2,749.53% -4,624.20% 0.00% -2,495.35% -609.14% -1,419.80%
Operating Margin
-1,365.51% -1,045.56% -1,334.44% -1,176.78% -213.33% -3,119.20% -6,350.09% 0.00% -2,755.38% -772.00% -1,542.68%
EBIT Margin
-1,365.20% -1,046.30% -1,336.15% -1,174.86% -201.09% -2,799.96% -4,968.78% 0.00% -2,553.97% -572.02% -1,399.31%
Profit (Net Income) Margin
-1,365.05% -1,046.27% -1,328.65% -1,154.48% -197.69% -5,652.17% -10,352.77% 0.00% -5,452.81% -1,274.25% -2,840.40%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 200.00% 200.00% 99.92% 100.14% 100.04% 99.94%
Interest Burden Percent
99.99% 100.00% 99.44% 98.27% 98.31% 100.93% 104.18% 198.08% 213.20% 222.66% 203.10%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-119.22% -223.40% -97.21% -130.52% -424.29% -865.36% -159.61% -165.91% -683.98% -118.68% -108.35%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-90.90% -130.02% -76.84% -99.42% -151.21% -145.59% -41.72% 0.00% -88.35% -39.21% -47.76%
Return on Assets (ROA)
-90.89% -130.02% -76.41% -97.70% -148.66% -293.90% -86.92% 0.00% -188.63% -87.34% -96.94%
Return on Common Equity (ROCE)
-119.22% -223.40% -97.21% -130.52% -424.29% -865.36% -159.61% -165.91% -683.98% -118.68% -108.35%
Return on Equity Simple (ROE_SIMPLE)
-98.51% -224.22% -56.11% -202.27% -1,160.42% -491.53% -132.08% -256.73% 1,291.93% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.20 -14 -23 -40 -54 -86 -39 -28 -32 -34 -60
NOPAT Margin
-955.85% -731.89% -934.10% -823.75% -149.33% -2,183.44% -4,445.06% 0.00% -1,928.77% -540.40% -1,079.87%
Net Nonoperating Expense Percent (NNEP)
-28.93% -44.29% -24.91% -30.75% -48.32% -278.60% -71.66% -99.73% -216.99% -55.50% -62.15%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 937.73% -23.95% -40.49%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
557.30% 337.95% 367.35% 268.67% 65.42% 723.36% 2,316.58% 0.00% 850.24% 261.43% 275.14%
R&D to Revenue
908.21% 807.60% 1,067.09% 1,008.11% 247.91% 2,495.85% 4,133.50% 0.00% 1,905.13% 510.57% 1,267.54%
Operating Expenses to Revenue
1,465.51% 1,145.56% 1,434.44% 1,276.78% 313.33% 3,219.20% 6,450.09% 0.00% 5,510.76% 1,544.00% 3,085.35%
Earnings before Interest and Taxes (EBIT)
-8.85 -20 -33 -57 -73 -110 -44 -43 -42 -36 -77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-8.81 -20 -32 -56 -71 -108 -41 -41 -41 -38 -79
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
6.91 42.10 6.74 12.14 57.35 2.32 1.12 0.42 0.00 1.01 0.97
Price to Tangible Book Value (P/TBV)
6.91 42.10 6.74 12.14 57.35 2.32 1.12 0.42 0.00 1.01 0.97
Price to Revenue (P/Rev)
95.70 196.45 159.66 69.32 9.77 26.68 87.45 0.00 16.33 22.77 25.84
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
76.92 188.67 134.10 60.74 8.91 9.65 0.00 0.00 5.60 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.02 0.03 0.01 0.01 0.12 0.41 0.28 0.72 -0.51 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.40 0.23 0.63 -0.47 0.00 0.00
Financial Leverage
-1.24 -1.52 -1.16 -1.22 -2.15 -1.91 -1.27 -1.12 -2.04 -1.23 -1.08
Leverage Ratio
1.31 1.72 1.27 1.34 2.85 2.94 1.84 1.70 3.63 1.36 1.12
Compound Leverage Factor
1.31 1.72 1.27 1.31 2.81 2.97 1.91 3.38 7.73 3.03 2.27
Debt to Total Capital
1.77% 2.96% 0.57% 1.41% 10.89% 29.27% 22.00% 41.92% -105.20% 0.00% 0.00%
Short-Term Debt to Total Capital
1.77% 2.96% 0.57% 1.41% 10.89% 1.11% 4.36% 5.54% -8.95% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 28.16% 17.65% 36.37% -96.26% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
98.23% 97.04% 99.43% 98.59% 89.11% 70.73% 78.00% 58.08% 205.20% 100.00% 100.00%
Debt to EBITDA
-0.02 -0.01 -0.01 -0.01 -0.01 -0.17 -0.48 -0.58 -0.09 0.00 0.00
Net Debt to EBITDA
1.38 0.75 1.93 0.74 0.43 0.62 1.92 0.86 0.43 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.17 -0.38 -0.50 -0.08 0.00 0.00
Debt to NOPAT
-0.03 -0.02 -0.01 -0.01 -0.01 -0.22 -0.50 -0.85 -0.11 0.00 0.00
Net Debt to NOPAT
1.96 1.06 2.74 1.04 0.57 0.78 2.00 1.28 0.56 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.21 -0.40 -0.74 -0.10 0.00 0.00
Altman Z-Score
6.75 19.50 23.51 3.48 -4.63 -5.87 -3.75 -9.30 -26.34 2.49 -0.92
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.50 1.96 7.98 2.45 1.09 2.89 5.89 4.76 0.74 12.94 8.07
Quick Ratio
3.40 1.68 7.62 2.31 0.91 2.68 5.74 4.68 0.66 12.61 7.89
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.24 -11 -24 -30 -43 -89 -52 -35 -9.68 -52 -50
Operating Cash Flow to CapEx
-4,055.55% -3,844.19% -3,929.25% -1,307.04% -1,667.09% -20,575.35% -159,169.19% -701,896.34% 0.00% 0.00% -921,300.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 -86.58 -28.26 -16.19 -2.51 -27.59 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 -96.94 -26.32 -17.61 -9.36 -22.33 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -97.41 -26.34 -17.61 -9.36 -22.33 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.07 0.12 0.06 0.08 0.75 0.05 0.01 0.00 0.03 0.07 0.03
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
7.28 6.83 2.61 2.33 9.28 0.86 0.27 0.00 1.26 9.29 20.33
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-3.23 -6.00 -4.58 -14 -25 -22 -9.23 -2.59 -24 -6.92 -16
Invested Capital Turnover
-0.37 -0.41 -0.46 -0.52 -1.87 -0.17 -0.06 0.00 -0.12 -0.40 -0.47
Increase / (Decrease) in Invested Capital
-2.96 -2.77 1.42 -9.25 -11 3.07 13 6.64 -22 18 -9.52
Enterprise Value (EV)
50 361 327 293 322 38 -1.24 -22 9.16 -5.63 -21
Market Capitalization
62 375 390 334 353 105 77 14 27 144 143
Book Value per Share
$0.24 $0.20 $1.05 $0.48 $0.10 $0.54 $0.55 $0.26 ($1.56) $11.69 $8.40
Tangible Book Value per Share
$0.24 $0.20 $1.05 $0.48 $0.10 $0.54 $0.55 $0.26 ($1.56) $11.69 $8.40
Total Capital
9.15 9.19 58 28 6.91 64 89 57 -3.37 142 148
Total Debt
0.16 0.27 0.33 0.39 0.75 19 19 24 3.54 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 18 16 21 3.24 0.00 0.00
Net Debt
-12 -15 -62 -41 -31 -67 -78 -36 -18 -149 -164
Capital Expenditures (CapEx)
0.11 0.35 0.71 2.30 2.74 0.48 0.03 0.01 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.09 -6.37 -5.06 -15 -28 -25 -11 -8.70 -29 -8.19 -18
Debt-free Net Working Capital (DFNWC)
9.25 8.78 58 27 4.02 61 87 51 -8.05 141 146
Net Working Capital (NWC)
9.08 8.50 57 26 3.27 60 83 48 -8.35 141 146
Net Nonoperating Expense (NNE)
2.65 6.01 9.63 16 17 137 52 57 58 46 97
Net Nonoperating Obligations (NNO)
-12 -15 -62 -41 -31 -67 -78 -36 -18 -149 -164
Total Depreciation and Amortization (D&A)
0.04 0.09 0.26 0.49 1.23 1.99 3.04 1.63 0.96 -2.34 -1.13
Debt-free, Cash-free Net Working Capital to Revenue
-476.80% -333.06% -207.51% -315.27% -76.72% -632.34% -1,222.77% 0.00% -1,781.48% -129.76% -319.66%
Debt-free Net Working Capital to Revenue
1,426.13% 459.14% 2,361.82% 550.47% 11.12% 1,546.44% 9,873.87% 0.00% -491.87% 2,236.70% 2,644.88%
Net Working Capital to Revenue
1,401.14% 444.92% 2,348.18% 542.30% 9.04% 1,528.40% 9,435.93% 0.00% -510.27% 2,236.70% 2,644.88%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($8.40) ($14.70) ($19.50) ($29.40) ($33.60) ($42.60) ($11.10) ($10.15) ($10.31) ($3.68) ($5.90)
Adjusted Weighted Average Basic Shares Outstanding
1.25M 1.62M 1.90M 2.15M 2.42M 4.16M 4.17M 4.17M 4.33M 10.92M 13.32M
Adjusted Diluted Earnings per Share
($8.40) ($14.70) ($19.50) ($29.40) ($33.60) ($42.60) ($11.10) ($10.15) ($10.31) ($3.68) ($5.90)
Adjusted Weighted Average Diluted Shares Outstanding
1.25M 1.62M 1.90M 2.15M 2.42M 4.16M 4.17M 4.17M 4.33M 10.92M 13.32M
Adjusted Basic & Diluted Earnings per Share
($8.40) ($14.70) ($19.50) ($29.40) ($33.60) ($42.60) ($11.10) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.05M 1.37M 1.67M 1.90M 2.13M 2.60M 4.10M 4.17M 10.49M 12.23M 17.74M
Normalized Net Operating Profit after Tax (NOPAT)
-6.20 -14 -23 -40 -54 -86 -39 -24 -32 -34 -60
Normalized NOPAT Margin
-955.85% -731.89% -934.10% -823.75% -149.33% -2,183.44% -4,445.06% 0.00% -1,928.77% -540.40% -1,079.87%
Pre Tax Income Margin
-1,365.05% -1,046.27% -1,328.65% -1,154.48% -197.69% -2,826.08% -5,176.38% 0.00% -5,445.17% -1,273.68% -2,841.99%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -107.20 -23.93 -20.07 -10.83 -19.28 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -83.60 -21.41 -13.08 -8.18 -18.22 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -107.67 -23.95 -20.07 -10.83 -19.28 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -84.07 -21.43 -13.08 -8.18 -18.22 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-5.75% -0.32% -9.07% -1.24% -3.60% -2.71% -1.99% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Corbus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Corbus Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
10,493,108.00 10,686,693.00 12,043,940.00 12,179,482.00 12,232,228.00 12,236,767.00 12,255,225.00 17,553,037.00 17,736,464.00 18,527,795.00 19,341,293.00
DEI Adjusted Shares Outstanding
10,493,108.00 10,686,693.00 12,043,940.00 12,179,482.00 12,232,228.00 12,236,767.00 12,255,225.00 17,553,037.00 17,736,464.00 18,527,795.00 19,341,293.00
DEI Earnings Per Adjusted Shares Outstanding
-0.76 -0.95 -1.30 -0.53 -1.40 -1.45 -1.90 -1.18 -1.31 -1.89 -1.95
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 187.96% 0.00% -17.88% 0.00% -70.07% -16.60% -11.42% -4.18%
EBITDA Growth
55.68% -29.59% -63.15% 22.64% -109.52% -69.08% -48.67% -384.32% -46.11% -88.06% -59.28%
EBIT Growth
59.40% -17.00% -55.55% 37.70% -124.61% -74.79% -52.60% -457.77% -45.38% -90.77% -58.71%
NOPAT Growth
44.37% -34.18% -63.42% -24.75% -105.50% -74.30% -57.48% -74.26% -22.90% -88.96% -59.00%
Net Income Growth
61.12% -13.81% -37.10% -18.80% -146.09% -76.67% -69.35% -115.69% -35.29% -98.38% -61.74%
EPS Growth
80.42% 56.10% 49.34% 68.11% -67.47% -60.00% -65.22% -98.31% 11.51% -25.69% 4.74%
Operating Cash Flow Growth
47.29% -14.64% -94.29% -82.12% -106.11% -85.61% -11.53% -45.50% -55.72% -78.48% -36.59%
Free Cash Flow Firm Growth
54.41% 1,994.26% -3,573.12% -278.16% -368.05% -512.74% -13.50% 77.78% 43.02% 46.37% 6.40%
Invested Capital Growth
-71.33% -294.48% 0.75% 71.72% 37.46% 73.35% -66.36% -137.55% -157.55% -206.36% -131.96%
Revenue Q/Q Growth
-100.00% 0.00% -100.00% 0.00% -64.32% -21.83% -14.38% 25.33% -0.57% -16.98% -7.39%
EBITDA Q/Q Growth
-35.02% -39.60% -46.97% 72.08% -265.69% -14.10% -29.23% 9.03% -10.33% -55.18% -7.13%
EBIT Q/Q Growth
-19.55% -41.27% -52.85% 75.86% -330.97% -9.94% -33.45% 11.78% -12.33% -56.42% -7.27%
NOPAT Q/Q Growth
4.76% -14.18% -41.11% 18.70% -56.88% 3.15% -27.49% 10.04% -10.64% -48.91% -7.28%
Net Income Q/Q Growth
14.00% -44.91% -37.87% 30.86% -78.15% -4.03% -32.16% 11.94% -11.74% 23.73% -7.75%
EPS Q/Q Growth
55.14% -8.43% -27.78% 48.70% -135.59% -3.60% -31.94% 38.42% -5.13% -47.15% 0.00%
Operating Cash Flow Q/Q Growth
-32.61% -12.25% -55.90% 21.52% -50.07% -1.08% 6.32% -2.39% -60.61% -15.86% 28.31%
Free Cash Flow Firm Q/Q Growth
-124.10% 286.91% -263.61% -141.75% 36.69% -64.82% 55.01% 52.67% -62.34% -55.14% 21.48%
Invested Capital Q/Q Growth
68.88% -152.66% 63.08% 2.56% 31.19% -7.65% -130.50% -39.13% 25.40% -28.05% -74.52%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% -668.06% 0.00% -93.12% -954.37% -1,375.42% -2,076.09% -1,506.88% -1,671.97% -3,125.09% -3,615.12%
Operating Margin
0.00% -686.75% 0.00% -267.57% -1,176.38% -1,457.53% -2,170.40% -1,557.87% -1,733.52% -3,109.11% -3,601.48%
EBIT Margin
0.00% -625.81% 0.00% -78.41% -947.06% -1,331.96% -2,076.09% -1,461.28% -1,650.78% -3,110.05% -3,602.23%
Profit (Net Income) Margin
0.00% -1,249.63% 0.00% -404.59% -2,019.99% -2,688.28% -4,149.69% -2,915.60% -3,276.60% -3,010.05% -3,502.23%
Tax Burden Percent
174.06% 99.71% 175.74% 51.91% 99.83% 99.95% 100.08% 99.88% 99.77% 100.00% 100.00%
Interest Burden Percent
111.84% 200.27% 102.49% 993.94% 213.66% 201.92% 199.73% 199.77% 198.95% 96.78% 97.22%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-119.05% -103.57% -102.65% -118.68% -89.77% -98.00% -111.29% -108.35% -133.40% -174.86% -227.06%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -20.70% 0.00% -5.37% -56.98% -74.09% -133.98% -49.87% -60.96% -125.87% -156.66%
Return on Assets (ROA)
0.00% -41.33% 0.00% -27.73% -121.53% -149.54% -267.80% -99.50% -120.99% -121.82% -152.32%
Return on Common Equity (ROCE)
-119.05% -103.57% -102.65% -118.68% -89.77% -98.00% -111.29% -108.35% -133.40% -174.86% -227.06%
Return on Equity Simple (ROE_SIMPLE)
-69.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.74 -7.69 -11 -8.82 -14 -13 -17 -15 -17 -25 -27
NOPAT Margin
0.00% -480.73% 0.00% -187.30% -823.47% -1,020.27% -1,519.28% -1,090.51% -1,213.47% -2,176.37% -2,521.04%
Net Nonoperating Expense Percent (NNEP)
-11.26% -15.46% -20.25% -12.27% -17.01% -16.80% -22.63% -16.43% -21.39% -8.29% -9.79%
Return On Investment Capital (ROIC_SIMPLE)
-5.97% -6.01% -7.11% -6.20% -10.79% -12.00% -18.49% -10.42% -13.47% -24.78% -30.91%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 257.69% 0.00% 81.04% 245.87% 301.75% 316.18% 252.48% 319.90% 430.84% 424.58%
R&D to Revenue
0.00% 429.06% 0.00% 186.52% 930.52% 1,155.78% 1,854.22% 1,305.39% 1,413.62% 2,678.26% 3,176.90%
Operating Expenses to Revenue
0.00% 1,373.50% 0.00% 1,068.52% 2,352.77% 2,915.07% 4,340.80% 3,115.74% 3,467.05% 3,109.11% 3,601.48%
Earnings before Interest and Taxes (EBIT)
-7.09 -10 -15 -3.69 -16 -18 -23 -21 -23 -36 -39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.66 -11 -16 -4.39 -16 -18 -23 -21 -23 -36 -39
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.25 3.85 1.65 1.01 0.51 0.76 1.68 0.97 1.32 1.70 1.56
Price to Tangible Book Value (P/TBV)
4.25 3.85 1.65 1.01 0.51 0.76 1.68 0.97 1.32 1.70 1.56
Price to Revenue (P/Rev)
251.68 149.44 76.78 22.77 8.13 10.96 17.56 25.84 31.72 34.07 26.10
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
187.76 104.70 28.08 0.00 0.00 0.00 5.78 0.00 5.32 10.95 3.91
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.16 0.02 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.04
Long-Term Debt to Equity
0.03 0.02 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.04
Financial Leverage
-1.11 -1.18 -1.09 -1.23 -1.06 -1.10 -1.08 -1.08 -1.07 -1.10 -1.22
Leverage Ratio
1.56 1.45 1.33 1.36 1.19 1.17 1.13 1.12 1.12 1.18 1.31
Compound Leverage Factor
1.75 2.90 1.36 13.51 2.53 2.37 2.25 2.23 2.23 1.14 1.28
Debt to Total Capital
14.02% 1.98% 1.34% 0.00% 0.94% 0.68% 0.33% 0.00% 0.00% 0.00% 3.61%
Short-Term Debt to Total Capital
11.49% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
2.53% 1.92% 1.34% 0.00% 0.94% 0.68% 0.33% 0.00% 0.00% 0.00% 3.61%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
85.98% 98.02% 98.66% 100.00% 99.06% 99.32% 99.67% 100.00% 100.00% 100.00% 96.39%
Debt to EBITDA
-0.51 -0.08 -0.05 0.00 -0.03 -0.01 -0.01 0.00 0.00 0.00 -0.03
Net Debt to EBITDA
3.35 4.30 3.97 0.00 2.82 2.15 1.69 0.00 0.00 0.00 0.96
Long-Term Debt to EBITDA
-0.09 -0.07 -0.05 0.00 -0.03 -0.01 -0.01 0.00 0.00 0.00 -0.03
Debt to NOPAT
-0.60 -0.09 -0.06 0.00 -0.03 -0.02 -0.01 0.00 0.00 0.00 -0.04
Net Debt to NOPAT
3.99 5.14 4.87 0.00 3.20 2.47 1.96 0.00 0.00 0.00 1.32
Long-Term Debt to NOPAT
-0.11 -0.09 -0.06 0.00 -0.03 -0.02 -0.01 0.00 0.00 0.00 -0.04
Altman Z-Score
4.39 7.58 7.72 3.18 -1.14 -1.48 -1.11 0.19 0.45 -2.49 -5.52
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.69 6.18 13.84 12.94 11.82 9.21 6.31 8.07 7.92 5.71 3.40
Quick Ratio
4.63 6.13 13.71 12.61 11.43 8.74 6.10 7.89 7.62 5.49 3.30
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.57 6.67 -11 -26 -17 -28 -12 -5.86 -9.51 -15 -12
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -426,183.33% -493,766.67% -141,593.33%
Free Cash Flow to Firm to Interest Expense
-4.25 10.22 -28.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-9.50 -13.72 -36.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-9.50 -13.72 -36.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.02 0.03 0.03 0.07 0.06 0.06 0.06 0.03 0.04 0.04 0.04
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
1.45 3.33 3.95 9.29 14.20 16.72 24.53 20.33 25.00 31.68 42.65
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-7.61 -19 -7.10 -6.92 -4.76 -5.13 -12 -16 -12 -16 -27
Invested Capital Turnover
-0.27 -0.27 -0.45 -0.40 -1.29 -0.63 -0.93 -0.47 -0.62 -0.49 -0.26
Increase / (Decrease) in Invested Capital
-3.17 -14 0.05 18 2.85 14 -4.71 -9.52 -7.50 -11 -16
Enterprise Value (EV)
307 339 91 -5.63 -67 -32 51 -21 28 56 20
Market Capitalization
412 484 248 144 65 84 155 143 167 174 132
Book Value per Share
$11.67 $11.75 $12.50 $11.69 $10.39 $9.07 $7.52 $8.40 $7.12 $5.52 $4.38
Tangible Book Value per Share
$11.67 $11.75 $12.50 $11.69 $10.39 $9.07 $7.52 $8.40 $7.12 $5.52 $4.38
Total Capital
113 128 153 142 128 112 92 148 126 102 88
Total Debt
16 2.53 2.05 0.00 1.21 0.76 0.31 0.00 0.00 0.00 3.18
Total Long-Term Debt
2.86 2.46 2.05 0.00 1.21 0.76 0.31 0.00 0.00 0.00 3.18
Net Debt
-105 -145 -158 -149 -132 -116 -104 -164 -139 -118 -112
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-12 -23 -10 -8.19 -7.33 -7.39 -14 -18 -13 -17 -31
Debt-free Net Working Capital (DFNWC)
109 124 149 141 126 109 91 146 125 101 84
Net Working Capital (NWC)
96 124 149 141 126 109 91 146 125 101 84
Net Nonoperating Expense (NNE)
7.06 12 17 10 20 22 30 26 29 9.70 11
Net Nonoperating Obligations (NNO)
-105 -145 -158 -149 -132 -116 -104 -164 -139 -118 -112
Total Depreciation and Amortization (D&A)
-0.57 -0.68 -0.41 -0.69 -0.12 -0.57 0.00 -0.64 -0.30 -0.18 -0.14
Debt-free, Cash-free Net Working Capital to Revenue
-712.73% -707.73% -320.83% -129.76% -91.74% -95.83% -155.77% -319.66% -250.92% -326.82% -620.36%
Debt-free Net Working Capital to Revenue
6,645.96% 3,844.50% 4,612.64% 2,236.70% 1,573.32% 1,420.87% 1,024.92% 2,644.88% 2,388.65% 1,985.30% 1,661.73%
Net Working Capital to Revenue
5,854.11% 3,842.12% 4,612.64% 2,236.70% 1,573.32% 1,420.87% 1,024.92% 2,644.88% 2,388.65% 1,985.30% 1,661.73%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.83) ($0.90) ($1.15) ($0.59) ($1.39) ($1.44) ($1.90) ($1.17) ($1.23) ($1.81) ($1.81)
Adjusted Weighted Average Basic Shares Outstanding
8.31M 11.05M 12.01M 10.92M 12.20M 12.24M 12.31M 13.32M 18.71M 19.41M 20.84M
Adjusted Diluted Earnings per Share
($0.83) ($0.90) ($1.15) ($0.59) ($1.39) ($1.44) ($1.90) ($1.17) ($1.23) ($1.81) ($1.81)
Adjusted Weighted Average Diluted Shares Outstanding
8.31M 11.05M 12.01M 10.92M 12.20M 12.24M 12.31M 13.32M 18.71M 19.41M 20.84M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.59) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
10.69M 12.04M 12.18M 12.23M 12.24M 12.26M 17.55M 17.74M 18.53M 19.34M 20.61M
Normalized Net Operating Profit after Tax (NOPAT)
-6.74 -7.69 -11 -8.82 -14 -13 -17 -15 -17 -25 -27
Normalized NOPAT Margin
0.00% -480.73% 0.00% -187.30% -823.47% -1,020.27% -1,519.28% -1,090.51% -1,213.47% -2,176.37% -2,521.04%
Pre Tax Income Margin
0.00% -1,253.31% 0.00% -779.37% -2,023.44% -2,689.50% -4,146.49% -2,919.15% -3,284.31% -3,010.05% -3,502.23%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-8.45 -15.36 -40.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-8.03 -11.80 -28.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-8.45 -15.36 -40.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-8.03 -11.80 -28.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Corbus Pharmaceuticals (NASDAQ:CRBP) remains heavily dependent on its cash reserves and capital markets while it funds research and development. The company reported $1.2 million of revenue in Q2 2026, down from $1.4 million in Q1 2026 and $1.3 million in Q2 2025. Revenue has been volatile and modest relative to operating costs, with quarterly revenue ranging from zero in parts of 2023 and 2024 to $4.7 million in Q4 2024.

Q2 2026 net loss narrowed to $35.0 million from $46.0 million in Q1, helped by the absence of the $24.3 million other operating expense recorded in Q1. However, the loss was substantially worse than the $17.7 million loss reported in the restated Q2 2025 period. Research and development spending increased to $31.2 million in Q2 from $19.8 million a year earlier, showing that Corbus continues to prioritize its pipeline despite the resulting cash burn.

Operating cash flow was negative $29.6 million in Q2 2026, compared with negative $25.6 million in Q1 and negative $16.6 million in Q2 2025. Based on the first-half operating cash burn of approximately $55.2 million, the company is consuming cash at a rapid pace. Still, Corbus held $23.4 million in cash and $94.6 million in short-term investments at June 30, 2026, or approximately $118.0 million in combined cash and short-term investments.

The balance sheet has limited debt, but liquidity declined during the quarter. Total current assets fell to $122.8 million from $143.6 million at March 31, while total liabilities increased to $24.7 million from $18.1 million. Corbus also raised $9.1 million through common equity issuance in Q2, which helped offset part of its operating cash burn but added to dilution risk.

  • Corbus held approximately $118.0 million in cash and short-term investments at the end of Q2 2026, providing a meaningful liquidity cushion.
  • Debt remains limited, with total liabilities of $24.7 million compared with $102.2 million of shareholders’ equity.
  • The Q2 net loss improved sequentially to $35.0 million from $46.0 million, primarily because Q1 included a $24.3 million other operating expense.
  • Investment maturities generated $27.0 million of cash in Q2, demonstrating that the company can actively manage its short-term investment portfolio to support liquidity.
  • Revenue carries no reported cost of revenue, producing a 100% gross margin; however, revenue of $1.2 million remains far too small to cover operating expenses.
  • Total assets declined approximately 12% sequentially, from $144.5 million to $127.0 million, reflecting cash usage and reductions in short-term investments.
  • Operating cash flow remained deeply negative at $29.6 million in Q2 and $55.2 million for the first half of 2026.
  • Quarterly revenue declined year over year, while the net loss widened from $17.7 million in Q2 2025 to $35.0 million in Q2 2026.
  • Research and development expense rose to $31.2 million in Q2, up roughly 58% from the restated Q2 2025 level, increasing the company’s cash requirements.
  • Corbus issued $9.1 million of common equity in Q2, and weighted-average shares outstanding rose to 19.4 million from 12.3 million in Q2 2025, highlighting substantial potential dilution for existing shareholders.
11/16/26 04:37 PM ETAI Generated. May Contain Errors.

Corbus Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Corbus Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Corbus Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$157.07 million in 2025, falling from -$8.85 million in 2015. The previous period was -$80.42 million in 2024. See Corbus Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Corbus Pharmaceuticals' total operating income in 2025 was -$85.31 million, based on the following breakdown:
  • Total Gross Profit: $5.53 million
  • Total Operating Expenses: $170.62 million

Over the last 10 years, Corbus Pharmaceuticals' total revenue changed from $648.38 thousand in 2015 to $5.53 million in 2025, a change of 752.9%.

In the past 12 quarters, Corbus Pharmaceuticals' cash and equivalents has ranged from $11.25 million in Q3 2023 to $30.25 million in Q3 2026, and is currently $30.25 million as of their latest financial filing in Q3 2026.

Corbus Pharmaceuticals had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2015.

Over the last 10 years, Corbus Pharmaceuticals' book value per share changed from 0.24 in 2015 to 8.40 in 2025, a change of 3,417.5%.



Financial statements for NASDAQ:CRBP last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners